Cumulus Neuroscience Presents Data at AD/PD™ 2025 Annual Meeting
Validation data presented at the 2025 Alzheimer's & Parkinson's Diseases (AD/PD) Conference confirms two novel NeuLogiq® Platform endpoints show greater...
Brain
Sensi.AI and Teepa Snow: In the Moment Care Coaching Is Here
Sensi brings renowned dementia and aging care expert Teepa Snow's proven strategies to the point of care—blending AI with human...
The Lilabean Foundation and CBTN Partner to Accelerate Breakthroughs in Pediatric Brain Cancer Research
WASHINGTON, April 3, 2025 /PRNewswire/ -- The Lilabean Foundation (LBF) is playing a critical role in advancing pediatric brain cancer research...
Winstrol Steroids: Winstrol Benefits, Winstrol Side Effects, Winstrol Results & Buy Winstrol Pills Alternatives Win-Max By CrazyBulk
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- “We’ve got several pro bodybuilding athletes ready and waiting to get to...
BetterLife Pharma Appoints Corporate Advisor
VANCOUVER, British Columbia, April 03, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB...
Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301
NDA Submission On-Target for Mid-2025KANSAS CITY, Kan., April 03, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing...
NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting
Three-year data from NeuroPace’s Post-Approval Study of the RNS® System in drug-resistant focal epilepsy to be shared in oral presentationMOUNTAIN...
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
MELBOURNE, Australia and SAN FRANCISCO, April 03, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the...
Arialief: We Tested It—Here’s Our Honest Arialief Review “Shocking Conclusion”
Is Arialief the breakthrough for nerve pain, numbness, and tingling through full-spectrum metabolic support? Read our real Arialief review and...
Prime Biome: We Tested It—Here’s My Honest Prime Biome Review After 117 Days!
Is Prime Biome’s “gut-skin synergy” the secret to beating bloating, revealing clearer skin, and maintaining steady weight management? Explore real...
NervGen Pharma Reports 2024 Year-End Financial Results and Provides Business Updates
Completed enrollment in the chronic cohort and commenced enrollment in the subacute cohort of its Phase 1b/2a clinical trial for...
PreveCeutical Announces Update to Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - April 2, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company"...
Zeto Unveils NeuroPulse, the First AI-Powered Status Epilepticus Software Using Full 10-20 EEG in Collaboration with encevis
SANTA CLARA, Calif., April 2, 2025 /PRNewswire/ -- Zeto, Inc., a fast-growing medical technology company revolutionizing EEG diagnostics with its...
Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial
HOUSTON, TX, April 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader...
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation...
FibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue Repair
HOUSTON, April 02, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued...
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
Rolling submission of BLA initiated for tividenofusp alfa; preparations ongoing for potential U.S. commercial launch in late 2025 or early...
Experience Onward Partners with Enthea to Expand Access to Psilocybin Treatment Through a Medical Tourism Benefit
Portland, Oregon--(Newsfile Corp. - April 2, 2025) - Experience Onward, Oregon's premier state-licensed psilocybin service center, is proud to announce...
Wellform MD is first in Iowa to Offer Leading-edge Technology Using Brain Stimulation to Treat Depression
Complimentary Launch Party April 24 to Showcase New Procedure ANKENY, Iowa, April 1, 2025 /PRNewswire/ -- Wellform MD, Des Moine's...
Leading Mental Health Provider SonderMind Expands Nationwide, Delivering High-Quality Mental Health Care in All 50 States
DENVER, April 1, 2025 /PRNewswire/ -- SonderMind, a leader in comprehensive, personalized mental health care, announced it is now serving...